The United States-based National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for CML suggest that NGS with a myeloid mutation panel should be considered for patients who present at an advanced disease stage or have disease progression to the advanced phases with no identifiable BCR::ABL1 kinase domain mutation. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.